Modern Amylin Molecules: Beyond Fibrillation Toward Developable Therapeutics
9:30 am - Wednesday 2nd December 2026
- Review how early fibrillation challenges were addressed through sequence modification and alternative peptide backbones
- Examine the remaining trade-offs between stability, aggregation, receptor pharmacology, concentration, formulation and manufacturability
- Separate developability challenges of therapeutic analogues from the biological significance of endogenous amylin aggregation in diabetes and other diseases
